Also known as: Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib and related therapies for pulmonary hypertension, including pulmonary arterial hypertension. It was incorporated in 2015 and is headquartered in San Diego, California.
Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.
Gossamer Bio's seralutinib narrowly missed its primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension, achieving a p-value of 0.0320 versus the prespecified threshold of 0.025, though showing stronger results in intermediate- and high-risk patients.
